I. INTRODUCTION
In recent years the use of Auger electron emitting radionuclides for targeted radionuclide therapy has shown promising results.
1-7 The low-energetic Auger electrons including the even lower energetic Coster-Kronig ͑CK͒ electrons are emitted by isotopes that decay by electron capture ͑EC͒ or have internal conversion ͑IC͒ in their decay. Depending on the isotope, many such electrons can be emitted per decay ͑from a few to more than 35͒ 8 almost instantaneously, thus, creating an electron cascade. The multiplicity and the short range in tissue ͑from a few nm to some m͒ of these Auger and CK electrons give rise to a high energy density created in the immediate vicinity of the decay site and, thus, a high, very localized absorbed radiation dose to the target region. 9 Additionally, the short range minimizes irradiation of the neighboring, normal cells, resulting in low observed unspecific radiotoxicities in cell experiments. 3, 10 The very short range of the electrons makes the localization of the radionuclides with respect to the sensitive targets in the cells ͑DNA͒ critical in determining effects from the radiation. If the decaying radionuclides are incorporated directly into the nuclear DNA or in close proximity to the DNA, extreme radiotoxicity is observed, resembling high-LET radiation with relative biological effectiveness ͑RBE͒ values much higher than 1. 11, 12 On the other hand, if the radionuclides are bound outside the cellular nucleus, e.g., on the cellular membrane, located in the cytoplasm or extracellular, the effects resemble those observed with low-LET radiation ͑e.g., X-rays͒ with low RBE values.
Some of the most commonly used Auger emitters for research in radionuclide therapy are 125 I, 123 I, 111 In, 67 Ga, and 201 Tl, which are all readily obtainable from commercial sources-the last four isotopes due to their wide use in diagnostics tracers ͑SPECT͒ in nuclear medicine.
3,4,13-15 However, the wide use of these isotopes in research in the field of radionuclide therapy is probably more a consequence of this accessibility than because of optimal radiation physics properties for cancer therapy. In principle, the optimal radionuclide for targeted radiotherapy must be one that, in addition to a proper half-life ͑hours→ days͒, is emitting radiation with a range that is long enough to allow irradiation of the target region, but at the same time, short enough to spare healthy tissue surrounding this region. Thus, a high proportion of gamma emission as seen with the four SPECT isotopes mentioned above is an undesirable property. For dosimetry calculations, however, the emission of gamma radiation is useful to determine the time-activity curve for the administered radiopharmaceutical in, e.g., the critical organs but the gamma intensity should be low to minimize unwanted dose to healthy tissues. Alternatively, the isotope used for therapy could emit no penetrating radiation and the time-activity curve and pharmacokinetics could then be evaluated before the treatment starts or simultaneously from a tracer study with a SPECT-or a PETisotope of the same element as the one used for the therapy. I. [16] [17] [18] [19] [20] There could be a need for increasing the scarce selection of available radionuclides suitable for targeted radionuclide therapy. In this study, we have performed a comparison of several Auger emitters based on theoretical dosimetry calculations at subcellular and macroscopic levels. From Sb is very suitable for SPECT imaging by scanning a Jaszczak SPECT phantom.
II. MATERIALS AND METHODS

II.A. Dose calculations and cellular S-values
The cellular dosimetry was performed using the formalism described in MIRD Cellular S-values 21 with a code programmed in MatLab 7.0.1. Using the geometric reduction factors by Berger 22 ͑Fig. 1͒ and stopping powers obtained from an empirical energy-loss expression using the continuous-slowing down approximation ͑CSDA͒, the dose per cumulated decay to all parts of the tumor cell could be calculated ͑Figs. 3-5͒. The energy-loss expression, i.e., the relationship between electron energy ͑E͒ and range ͑R͒ in unit density matter was taken as experimentally determined by Cole for energies higher than 0.4 keV. 23 Below 0.4 keV, a fit was made to Cole's experimental data because these are not well described by Cole's expression. The following expression was used: E = −53 111R 3 + 1491.4R 2 + 11.893R, with E in keV and R in m. Using this approach, it is assumed that secondary electrons ͑delta rays͒ are absorbed locally. In calculating the S-values, this assumption has been shown to be valid from comparison with Monte Carlo transport codes for electron energies below several hundred keV. 21 The radioactivity in the cell was assumed uniformly distributed over one of the following spherical symmetric cell compartments: the cell surface ͑CS͒, cytoplasm ͑Cy͒, or cell nucleus ͑N͒. As target region, only the cell nucleus was considered in calculating the S-values. The contribution to the cellular absorbed mean dose from gamma radiations was not taken into account since this is negligible as reported in MIRD Cellular S-values. 21 The radiation spectra were either obtained from the Report No. 2 of AAPM Nuclear Task Group No. 6 by Howell, 8 if possible, or from the Nuclear Decay Data Files for Dose Calculation ͑DECDC͒. 24 The spectra from DECDC contain data for the K-, L-, and M-shell electrons, while the spectra reported by Howell are more complete by including the lowenergy N-and O-shell electrons. The omission of these very low-energy electrons was seen to be insignificant for sphere diameters larger than 1 m in agreement with the findings reported by Howell. 8 In calculating the tumor-to-normal-tissue dose ratios ͑TNDs͒ per disintegration, the dose to the normal tissue was obtained from the tabulated dose factors ͓͑DFs͒, equivalent to the MIRD organ S-values͔, in the Radiation dose assessment resource ͑RADAR͒.
25 Only the whole-body to wholebody dose contribution was considered, i.e., the S͑whole-body← whole-body͒ assuming a uniform activity distribution in this compartment. The TND calculation was done on a simple per decay basis, i.e., differences in physical and biological half-lives and resulting differences in cumulated decays were not taken into account at this stage.
II.B.
119
Sb and
117
Sb productions
As the above calculations identify 119 Sb as a potent isotope for radionuclide therapy, the proton irradiation yields of this isotope and its SPECT-analogue 117 Sb were measured. Sn, respectively, both from Campro Scientific͒ was made by either dissolving the tin metal ͑5-30 mg͒ directly in hot 2.5 M KOH containing H 2 O 2 or by dissolving the tin metal in 0.5 ml hot, concentrated HCl containing H 2 O 2 followed by adding 1.0 ml 10 M KOH to the solution. The latter route was used for larger quantities of the tin metal to speed up the etching process. The resulting solution was then diluted to 0.25 M KOH with distilled water and transferred to an electroplating cell. A coin-like silver plate with a diameter of 29 mm and thickness of 5.2 mm was used as backing ͑see Sn targets were determined from the weight and surface area of the electroplated tin to be 7.4 and 5.5 mg/ cm 2 , respectively.
II.B.1. Target preparation
FIG. 1. The dose to a given point P at radius r is calculated via the geometrical reduction factor G͑r , r s , r i , x͒. This factor gives the fraction of the spherical shell centered on P with radius x and thickness dx that lies within the source volume ͑shaded volume in the figure͒.
II.B.2. Irradiations and activity measurements
The electroplated targets were mounted in a water cooled irradiation chamber with an aluminium proton energy degrader in front of the target. The irradiations were done using the external proton beam from the beamline of the GE PETtrace Cyclotron at the Hevesy Laboratory at Risoe National Laboratory. The targets were irradiated with a constant beam current of 15 A with a collimated beam of 10 mm in diam for 1 h. The integrated beam current was taken as reported by the cyclotron software. The proton energy was determined from prior irradiations by irradiating a precision Cu monitor foil. The energy was measured to be 10.1 MeV behind the energy degrader using the monitor reactions nat Cu͑p,x͒ 63 Zn and nat Cu͑p,x͒ 62 Zn with the recommended cross sections given by IAEA. 26 The produced 117 Sb activity was measured using a calibrated Ge detector ͑Princeton Gamma-Tech, LGC 5͒ with the detector software Genie 2000 ͑version 3.0͒. The energy and efficiency calibrations were done using 152 Eu and 133 Ba point sources ͑AEA Technology͒. The irradiated target was measured several times with a distance ranging between 20 cm and 300 cm from the detector in the time interval from 1 h to 4 days after EOB. The 117 Sb activity was determined primarily from the 158.56 keV ␥-ray ͑I ␥ :86%͒. 27 By measuring the target after the 117 Sb had decayed, it was possible to correct the 117 Sb activity for any simultaneously produced 117m Sn ͑T 1/2 = 13.60 d͒, which emits a ␥-ray of the same energy ͑158.56 keV͒.
For determining the produced 119 Sb activity, a low-energy Ge detector ͑Canberra, GL0055P͒ was used. This setup made it possible to discriminate the 23.87 keV ␥-ray stemming from the 119 Sb decay from the characteristic X-rays simultaneously emitted from both the Sn layer was calculated to be 4% and this correction was included in the activity measurement.
II.C.
117
Sb SPECT
To demonstrate the imaging capabilities of the 117 Sb isotope, a planar scintigraphy and a single photon emission computed tomography ͑SPECT͒ scan was made of a Jaszczak SPECT phantom.
II.C.1.
117 Sb production
The enriched 117 Sn target used in the yield measurements was irradiated using the setup described above with a 15 A proton beam ͑14.9 A mean current͒ for 90 min. After the Sb was dissolved, the radionuclidic purity of the resulting solution was measured using the Ge detector ͑Princeton Gamma-Tech, LGC 5͒ described above. Because no radioactive tin impurities were detected in the solution, no attempt was made to separate the tin and the produced radioantimony.
II.C.2. Planar scintigraphy and SPECT
The planar scintigraphy ͑PS͒ and the SPECT scan were both made using the Jaszczak SPECT phantom. The PS was made of the phantom with the cold rod insert only. The phantom was filled with water containing 202 MBq 117 Sb to a height of 8.8 cm, i.e., to just above the cold rod insert. The phantom was placed on the collimator face of one of the detectors of a Philips SKYLight dual-head gamma camera with medium energy general purpose ͑MEGP͒ collimators mounted. A total of 10 million counts were acquired.
The SPECT scan was made with the phantom completely filled with water containing 153 MBq of 117 Sb. This time, both the cold rod insert and the six solid spheres ͑cold spots͒ were mounted in the phantom. To simulate a hot spot, we additionally mounted a small cylindrical vial ͑10 mm, height 25 mm͒ filled with water containing 15 MBq of 117 Sb offcenter in the volume above the cold rod insert. The phantom was then placed on its side on the bed and scanned. The acquisition consisted of 32 frames of 30 sec with the MEGP collimators mounted on the cameras.
The image reconstruction was performed using filtered backprojection with a Hanning filter followed by standard attenuation correction. All images were then transferred to MatLab 7.0.1 for noise reduction and background subtraction.
III. RESULTS AND DISCUSSION
III.A. Cellular S-values and TND
The calculated cellular S-values for 119 Sb activity located on the cell surface, in the cytoplasm, or in the cell nucleus, respectively, for different sizes of cells and cell nuclei can be seen in Table I For radioactivity bound to the cell membrane or distributed uniformly in the cytoplasm, it can be seen that 119 Sb clearly delivers the highest dose to the cell nucleus of the radionuclides tested. The results for the cell membrane bound activity are in agreement with those reported by Sastry et al. 28 who calculated that the 20 keV conversion and K-Auger electrons from 119 Sb are optimal for irradiating the nuclei of cells from radiolabeled monoclonal antibodies bound to the cell surface. For radioactivity distributed in the cell nucleus, 119 Sb delivers a high dose compared to most of the radionuclides tested-it is only exceeded by 201 Tl and 193m Pt.
However, in radionuclide therapy, the effect of a given treatment is usually limited by the absorbed dose to the critical organs, i.e., the dose-limiting organs and, thus, it is necessary to include the normal tissue dose. 29, 30 For very small tumors and micrometastases with Auger-emitters located in the cell nuclei, the self-dose is dominating 31 and the crossdose contribution may then be neglected. Consequently, it was possible to calculate a tumor-to-normal-tissue dose ratio ͑TND͒ per disintegration for decays in the tumor cell nuclei and decays in the total body as described in Sec. II A. The results for different nuclides normalized to the TND value for 119 Sb for cells with a radius of 8 m and a nucleus radius of 6 m can be seen in Fig. 6 .
From Fig. 6 it can be seen that despite the high absorbed doses delivered to the tumor cell nucleus per disintegration from 201 Tl and 193m Pt ͑Fig. 3͒, their TND values are low compared to some of the other isotopes tested. This is due to the abundance of relatively high energy conversion electrons ͑above 50-100 keV͒ emitted in the decays of these isotopes with ranges up to more than 0.2 mm in tissue 8 in addition to the abundant photon emission ͑␥-and especially X-rays͒ from the 201 Tl decay. Based on a theoretical study of different isotopes located in varying sizes of spherical tumors in a patient ͑modeled as an ellipsoid͒, Bernhardt et al. concluded that to achieve a high TND in the treatment of small tumors ͑Ͻ1000 cells͒, the energy of the emitted electrons should be ഛ40 keV. 29 In addition, the photon-to-electron energy emission ratio, p / e, should be ഛ2 ͑the p / e of 201 Tl is 2.1͒. These statements are in agreement with our findings. For heterogeneous radioactivity distributions, which are often seen in larger tumors, the cross-irradiation component resulting from these high energy conversion electrons would result in a more uniform dose distribution, though, and, thus, could be an advantage. However, it has been shown that in therapy of neuroendocrine tumors with the Auger-and conversion electron emitter 111 In as 111 In-DTPA-Octreotide, it is the Auger electrons and not the conversion electrons ͑145-245 keV͒ that are responsible for the observed therapeutic effects. The normalized TND values for activity distributed in the cytoplasm or on the cell membrane can also be seen in Fig.   FIG. 4 . The dose to various parts of a cell ͑nuclear radius: 6 m, cellular radius: 8 m͒ per cumulated decay as a function of radius for a uniform activity distribution in the cell cytoplasm.
FIG. 5. The dose to various parts of a cell ͑nuclear radius: 6 m, cellular radius: 8 m͒ per cumulated decay as a function of radius for a uniform activity distribution on the cell surface. 6 . These results are only valid for single cells or very small cell clusters consisting of a low number of cells due to the omission of the cross-dose contribution, which starts to account for a considerable part of the total tumor cell dose when the cluster size increases. 31 In order to calculate the TND values for larger cell clusters, both the cluster size, the cluster and cell geometries, and the activity distributions have to be taken into account. Since the rationale of using Auger electrons for cancer therapy is to be able to exploit the possible high-LET-like biological effects, so far only obtained from nuclear localization of the Auger emitter, 2,9,12,32 these calculations have not been done in this study.
From Fig. 6 it can be seen that 119 Sb has the highest TND values of the isotopes tested for both nuclear, cytoplasmic, and membrane bound activity distributions. For the nuclear distribution Er for targeted radiotherapy has been suggested recently by Beyer et al. 34 Even though it has a p / e ratio of 4.7 caused by the abundant X-ray emission, and the dose delivered to the cell nucleus per 165 Er disintegration is quite low compared to the other radionuclides tested, it has a high TND. For comparison, the p / e ratio for 119 Sb is 0.9 ͑the value of 0.09 reported by Bernhardt et al. 29 must be a misprint͒. Thus, 165 Er may be another promising radionuclide for therapy.
Still, of all the radionuclides considered in this study,
119
Sb seems to be the most promising radionuclide for targeted radiotherapy of small tumors, micrometastases, or single cancer cells. This is in good agreement with the theoretical study of Bernhardt et al. 29 Using predefined criteria and, as described above, assuming the tumor to be a sphere and the body an ellipsoid, both with uniform activity distributions, five isotopes were found suitable for targeted radiotherapy of small tumors, among them 119 Sb.
III.B.
117
Sb SPECT
Internal dosimetry constitutes a very important part of radionuclide therapy but because of the absence of penetrating photon emission from the 119 Sb decay, the time-activity curves and normal-tissue uptake will be difficult to determine from this radionuclide-the same effect as observed with 90 Y. 16 However, by a tracer study with SPECT using the isotope 117 Sb, it should be possible to partly overcome this. Sb is a suitable imaging isotope. It was possible to locate both the hot-spot and the three largest spherical cold-spots ͑38 mm, 31.8 mm, and 25.4 mm͒ in the SPECT scan and all the cold-rods were visible in the planar scintigraphy. The coldrods were not visible in the SPECT scan, though, but this was primarily due to a too low number of counts in the separate frames. Sb reaction. This means that the extrapolated production yield may be an underestimate of the real obtainable yield using the larger amount of enriched target material than what was used in this study.
III.C.
If even higher activities are needed, this can be achieved by either increasing the irradiation time or by a further increase in the target thickness. Another approach is to use an inclined target/beam geometry to allow a high increase in the beam current resulting in a considerable increase in the obtainable yield. Such high current irradiations ͑ϳ200 A͒ on a nat Sn target using a dedicated PET cyclotron have recently been performed in our department ͑unpublished data͒ demonstrating the capability of producing several tens of GBqs of therapeutic isotopes locally. Hence, it will be possible to produce the amounts of 119 Sb radioactivity that is required for initial patient studies and clinical trials in radionuclide therapy using a small medical cyclotron.
The shorter half-life of 117 Sb and the need for a much smaller amount of radioactivity for each patient in a diagnostic study than for therapy, makes the 117 Sb production less demanding than the 119 Sb production. Using the same extrapolation conditions as above, it will be possible to produce approximately 23 GBq of 117 Sb at EOB in a 4 h irradiation, which should be sufficient for several patient scans.
IV. CONCLUSION
Based on theoretical dosimetry calculations for different subcellular distributions of several Auger-electron emitting isotopes, we have identified 119 Sb as being a potent radionuclide for targeted radiotherapy of small tumors, micrometastases, and single cancer cells. Using the MIRD-model, we have calculated the cellular S-values for this isotope. In addition, we have measured the proton irradiation yields for the production of 119 Sb and the corresponding imaging isotope 117 Sb using a low-energy cyclotron. From a planar scintigraphy and a SPECT scan of a Jaszczak phantom, we have shown that the latter isotope is well suited for SPECT-based patient-specific dosimetry of an 119 Sb-labeled radiopharmaceutical. The production yields show that it will be possible to produce both isotopes with a standard PET-cyclotron in sufficient quantities for patient imaging and therapy. Sb. The planar scintigraphy was acquired with the phantom standing on its end on top of the collimator.
